359 related articles for article (PubMed ID: 16984898)
1. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
[TBL] [Abstract][Full Text] [Related]
3. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
[TBL] [Abstract][Full Text] [Related]
6. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
7. Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.
López Galera RM; Ribera Pascuet E; Esteban Mur JI; Montoro Ronsano JB; Juárez Giménez JC
Eur J Clin Pharmacol; 2008 Dec; 64(12):1235-6. PubMed ID: 18712519
[No Abstract] [Full Text] [Related]
8. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.
Meaden ER; Hoggard PG; Newton P; Tjia JF; Aldam D; Cornforth D; Lloyd J; Williams I; Back DJ; Khoo SH
J Antimicrob Chemother; 2002 Oct; 50(4):583-8. PubMed ID: 12356805
[TBL] [Abstract][Full Text] [Related]
9. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.
Boffito M; Kurowski M; Kruse G; Hill A; Benzie AA; Nelson MR; Moyle GJ; Gazzard BG; Pozniak AL
AIDS; 2004 Jun; 18(9):1291-7. PubMed ID: 15362661
[TBL] [Abstract][Full Text] [Related]
10. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
[TBL] [Abstract][Full Text] [Related]
11. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
14. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
Robillard KR; Chan GN; Zhang G; la Porte C; Cameron W; Bendayan R
Antimicrob Agents Chemother; 2014; 58(3):1713-22. PubMed ID: 24379203
[TBL] [Abstract][Full Text] [Related]
15. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
16. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
[TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
Seminari E; Guffanti M; Villani P; Gianotti N; Cusato M; Fusetti G; Galli A; Castagna A; Regazzi M; Lazzarin A
Eur J Clin Pharmacol; 2005 Aug; 61(7):545-9. PubMed ID: 16041598
[TBL] [Abstract][Full Text] [Related]
19. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
20. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
Koks CH; Crommentuyn KM; Hoetelmans RM; Burger DM; Koopmans PP; Mathôt RA; Mulder JW; Meenhorst PL; Beijnen JH
Br J Clin Pharmacol; 2001 Jun; 51(6):631-5. PubMed ID: 11422025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
